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BACKGROUND: The optimal interval between two consecutive mammograms is uncertain. The UK Frequency Trial did not show a
significant difference in breast cancer mortality between screening every year (study group) and screening every 3 years (control
group). In this study, the trial is simulated in order to gain insight into the results of the trial and to predict the effect of different
screening intervals on breast cancer mortality.
METHODS: UK incidence, life tables and information from the trial were used in the microsimulation model MISCAN–Fadia to simulate
the trial and predict the number of breast cancer deaths in each group. To be able to replicate the trial, a relatively low sensitivity had
to be assumed.
RESULTS: The model simulated a larger difference in tumour size distribution between the two groups than observed and a relative risk
(RR) of 0.83 of dying from breast cancer in the study group compared with the control group. The predicted RR is lower than that
reported from the trial (RR 0.93), but within its 95% confidence interval (0.63–1.37).
CONCLUSION: The present study suggests that there is benefit of shortening the screening interval, although the benefit is probably not
large enough to start annual screening.
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In randomised controlled trials, mammography screening has
been shown to reduce breast cancer mortality rates (Tabar et al,
1992; Nystrom et al, 1993, 2002). The more frequently a woman has
screening exams, the larger the probability of having an early
diagnosis, and the larger the mortality reduction might be.
However, with more frequent exams, the potential of false-positive
exams and overdiagnosis will also increase (Jansen and Zoetelief,
1997; Christiansen et al, 2000). There is no consensus on the
optimal screening interval (i.e., the time between two consecutive
mammograms), as is illustrated by the variety of screening
intervals used throughout the world. Most European screening
programmes use an interval of 2 years (e.g., The Netherlands,
Sweden), whereas other countries use a 3-year interval (United
Kingdom, Malta). Even within the same country, screening
recommendations vary: in the United States, the American Cancer
Society recommends annual screening starting at the age of
40 years (Smith et al, 2010), whereas the US Preventive Services
Task Force recently changed their recommendation to biennial
screening from age 50 to 74 years (US Preventive Services Task
Force, 2009).
Two randomised trials compared a 1-year screening interval
with a 3-year screening interval, one in women between age 40 and
49 years (Klemi et al, 1997) and one in women between age 50 and
62 years (Breast Screening Frequency Trial Group, 2002). The
latter, the UK Breast Screening Frequency Trial, was conducted
from 1989 to 1996, in order to evaluate the difference in
(predicted) breast cancer mortality between screening annually
and screening once every 3 years (Breast Screening Frequency
Trial Group, 2002). The tumours in the trial group, offered annual
screening, were significantly smaller than those diagnosed in the
control group, offered screening every 3 years. For node status and
histological grade, no significant difference between the two
groups was found. The initially reported relative risk (RR)
predicted on the basis of two prognostic indices showed a
nonsignificant reduction in predicted breast cancer mortality
(Breast Screening Frequency Trial Group, 2002). The results were
later updated with results on the actual observed number of breast
cancer deaths in both groups again showing a nonsignificant
reduction in breast cancer mortality. Women in the study group
had an RR of 0.93 (95% confidence interval (CI) 0.63–1.37) of
dying from breast cancer compared with women in the control
group (Duffy and Blamey, 2008).
This finding was (slightly) surprising and raised the question
why no significant difference was found between the two groups. It
might be that there is truly only a very small mortality benefit of
more frequent screening, or there might be other reasons why no
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difference is found between the two groups, for example, a lack of
power or low sensitivity of mammography. Most policy predic-
tions are based on the assumption that increasing the screening
frequency will lead to more early diagnoses and consequently in a
reduction in breast cancer mortality, hence it is crucial to get more
insight in the results of this trial. A simulation model is ideally
suited to evaluate the effect of different screening intervals on
mortality, because the effect of different screening test sensitivities
can be assessed and the model guarantees that trial populations are
identical, except for the factors investigated.
In the present study, the UK Breast Screening Frequency Trial
was simulated using the microsimulation model MIcrosimulation
of SCreening ANalysis–Fatal diameter (MISCAN–Fadia), in order
to gain insight into the results of the trial and estimate the effect of
different screening intervals on breast cancer mortality.
MATERIALS AND METHODS
Model overview
MISCAN–Fadia is a microsimulation model developed within the
Cancer Intervention and Surveillance Modeling Network (CISNET)
(Tan et al, 2006). Briefly, the model simulates life histories in the
absence of screening and then assesses how these life histories
change as a consequence of screening programmes. MISCAN–
Fadia explicitly models invasive tumour growth in combination
with the concept of a fatal diameter. The model has been described
in detail elsewhere (Tan et al, 2006) and information about the
model can be found on the CISNET website (http://cisnet.cancer.
gov/). A detailed description of the model components and
model quantification for the present study is presented in the
Appendix.
In brief, for the present study, the model simulates a population
of women between the ages of 50 and 62 years in the year 1992 (i.e.,
the middle year of the trial) using the life tables of the UK female
population. Among those who develop breast cancer, the natural
history is modelled as a continuously growing tumour. Each
tumour has a size (the fatal diameter, which differs between
tumours) at which diagnosis and treatment will no longer result in
cure given available treatment options. If the tumour is diagnosed
(either on the basis of clinical presentation with symptoms or by
screening) and treated before it has reached its fatal diameter, the
woman will be cured and will die of non-breast cancer causes.
Variation between tumours is modelled by probability distribu-
tions of tumour growth, threshold diameter of screen detection,
clinical diagnosis diameter and fatal disease diameter.
When a screening programme is applied, the pre-clinical
tumour may be detected by screening. Each simulated tumour
has a diameter at which it will be clinically diagnosed as well as a
screen-detection threshold diameter. For the latter, screening test
sensitivity is 0% below and 100% above this diameter. The
threshold diameter is assumed to decrease with age and calendar
year. Screening benefits result from detection of more tumours at a
non-fatal size (Tan et al, 2006).
Model calibration and validation
Several approaches have been used to assess the internal reliability
of MISCAN–Fadia and the validity of the results against external
data, as previously reported (Tan et al, 2006). For the present
study, age-specific breast cancer incidence rates for the years
1975–1988, that is, before the implementation of the National
Health Service Breast Screening Programme (NHSBSP) were used
to estimate age-specific parameters for disease onset. The
age-specific breast cancer incidence rates for the year 1988 as
simulated by MISCAN–Fadia were compared with the observed
incidence rates for the year 1988 in the United Kingdom.
UK breast screening frequency trial
Five screening units participated in the trial held between 1989 and
1996 (Breast Screening Frequency Trial Group, 2002) (see Figure 1
for an overview of the trial design). A total of 99 389 women aged
50–62 years who had been invited to a prevalence screen in the
NHSBSP were randomised to a conventional screen after an
interval of 3 years (control group, n¼ 50 216), or to three annual
screenings (study group, n¼ 49 173). For the primary analysis,
only women who attended the prevalence screen and in whom no
cancer was found at the prevalence screen were included
(n¼ 38 492 in the control group and n¼ 37 530 in the study
group). The attendance rate in the control group, among women
who had attended the prevalence screen, was 85%. In the study
group, attendance rates at the three yearly screens were 78%, 78%
and 81%, respectively, (Breast Screening Frequency Trial Group,
2002).
Trial replication and mortality prediction
Initially, the model based on data from randomised screening
trials (extrapolated to the current period) and US data simulated a
more favourable tumour size distribution than observed in the
trial for both groups. Therefore, the threshold diameter and
diameter of clinical detection were estimated using data from the
Frequency Trial on the numbers of invasive breast cancers in both
groups of the trial split out by tumour size and detection mode
(see Appendix). Compared with the initially used values, the
estimated values were somewhat higher for the diameter of clinical
detection and the threshold diameter, corresponding to a lower
screening sensitivity.
Subsequently, this fitted model was used to predict the
number of breast cancer deaths from cancers diagnosed during
the trial period in each group with a follow-up period up to 2006.
From these numbers, a predicted RR of dying from breast cancer
in the study group compared with the control group was
calculated.
12 months
24 months
36 months
n = 38 492 (77%)
n = 50 216
1st Screen
attendance, 78%
2nd Screen
attendance, 78%
3rd Screen
attendance, 81%
1st Screen
attendance, 85%
Randomised n = 49 173
Prevalence screen n = 37 530 (76%)
Control group Study group
Time
Figure 1 A schematic overview of the UK Breast Screening Frequency
Trial.
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In addition, we investigated the effect of a longer follow-up
period (i.e., until all women have died), a higher sensitivity (using
the initial value for the threshold diameter) and full compliance
(i.e., 100% attendance rates) on the predicted RR.
RESULTS
Model calibration and validation
The observed age-specific incidence rates in the year 1988 as
reported by the NHSBSP were accurately reproduced by MISCAN–
Fadia (Figure 2). For each 5-year age group (35–79 years), the
difference between the observed and simulated incidence rates was
o10%.
Trial replication and mortality prediction
The model with the threshold diameter and diameter of clinical
detection estimated based on the trial data, simulated a total of
523 (445 invasive) breast cancers in women who attended the
prevalence screen compared with a total of 535 (443 invasive)
cancers observed in the trial. The numbers of detected breast
cancers and percentages screen detected, and clinically detected
cancers are close to the observed numbers and percentages in both
the groups (Table 1).
For the trial period, the cumulative incidence (number of
invasive breast cancers detected) in both groups over time since
prevalence screen, as observed in the trial and simulated by the
model, is shown in Figure 3.
The model simulated a more favourable tumour size distribu-
tion in the study group than in the control group, in line with what
was observed in the trial (Table 2). For the control group, the
simulated size distribution was somewhat less favourable (61%
small tumours simulated vs 66% observed) and for the study
group, the simulated size distribution was somewhat too favour-
able (77% small tumours simulated vs 73% observed). Thus, the
model simulated a larger difference in size distribution between
the control and study group than observed.
In the control group, 55 breast cancer deaths from cancers
diagnosed in the trial were observed during the median follow-up
of 162 months (Duffy and Blamey, 2008), compared with 54 deaths
predicted. In the study group 50 breast cancer deaths were
observed (Duffy and Blamey, 2008), whereas the model predicted
45 breast cancer deaths. The predicted difference between the
number of deaths in the control group and the study group was
larger than the observed difference, corresponding to a predicted
RR of 0.83 of dying from breast cancer in the study group
compared with the control group.
A longer follow-up period (life-time) had no effect on the
predicted RR (Table 3). Increasing the sensitivity led to a higher
percentage of screen-detected cancers in both groups (78% in the
study and 58% in the control group) and to a lower predicted RR
of 0.81, as did increasing the attendance to 100%. The combination
of full compliance and higher sensitivity led to a predicted RR
of 0.77.
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Figure 2 Age-specific breast cancer incidence rates in the UK for the
year 1988 as observed and simulated by MISCAN–Fadia.
Table 1 Cumulative number of breast cancers by detection mode in the
control group (3-year screening interval) and screen group (1-year
screening interval) as observed in the Frequency Trial and simulated by
MISCAN–Fadia (prevalence screen attenders only)
Observed Simulated
Control Study Control Study
Number (%) Number (%) Number (%) Number (%)
Screen detected 135 (54) 206 (72) 129 (51) 195 (72)
Clinically detected 113 (46) 81 (28) 123 (49) 77 (28)
Total 248 287 251 272
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Figure 3 Cumulative incidence (number of invasive breast cancers) over
time since prevalence screen in the control and study group as observed in
the Frequency Trial (obs) and simulated by MISCAN–Fadia (sim).
Table 2 Number (%) of detected cancers (invasive by tumour size) in
the control and study group as observed in the Frequency Trial and
simulated by MISCAN–Fadia
Observed Simulated
Control Study Control Study
Number (%) Number (%) Number (%) Number (%)
DCIS 40 (16) 52 (18) 27 (11) 50 (19)
Invasive cancers 208 (84) 235 (82) 224 (89) 227 (81)
By tumour size
1–20mm 134 (66) 170 (73) 136 (61) 170 (77)
21–50mm 64 (32) 59 (25) 78 (35) 48 (22)
50+ mm 5 (2) 4 (2) 10 (5) 3 (2)
Not known 5 2 0 0
Total 248 287 251 272
Abbreviation: DCIS¼ ductal carcinoma in situ.
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DISCUSSION
The present study suggests that there is benefit in terms of a
reduction in breast cancer mortality associated with shortening the
screening interval from 3 years to 1 year. The results show that if
the available information from the UK Breast Screening Frequency
Trial is used in a microsimulation model that is based on the
results of randomised screening trials including a large(r) number
of women, a larger effect of shortening the screening interval is
predicted. The predicted RR of breast cancer death for the study
group (offered three annual screens) compared with the control
group (offered one screen after 3 years) was 0.83. The effect of
more frequent screening is predicted to be larger when the
attendance rate or screening test sensitivity is increased.
The microsimulation model used in the present study fitted the
data better when a somewhat higher threshold diameter,
corresponding to a lower screening test sensitivity, and diameter
of clinical detection is used compared with a model based on data
from randomised screening trials (extrapolated to the current
period) and from the US. Thus, it seems that the screening test
sensitivity in the trial was relatively low, which is in line with
previously reported results showing that screen-detected as well as
interval cancers could benefit from improved sensitivity (Warren
et al, 2003). The results of the present study indicate that when the
screening test sensitivity is higher, the effect of shortening the
screening interval will be somewhat larger. This finding is
important when considering shorter screening intervals for certain
risk groups. For example, it has been hypothesised that women
with high breast density might benefit more from additional
frequent screening, because they have a higher risk of breast
cancer (Kerlikowske et al, 2010). However, screening test
sensitivity has been found to be lower in women with high breast
density (Carney et al, 2003). The present study shows that the
lower sensitivity in this group might offset some of the potential
benefit of more frequent screening in this group.
The most important limitation of the current study is the
relative paucity of data available to simulate the trial. More
information (e.g., on the age distribution of participants and
tumour size distribution of screen vs clinically detected cancers in
both groups) might further improve the model, and consequently
the model predictions. In addition, detailed information on the
attendance rates was not available. For example, the non-
attendance in the study group was somewhat higher than in the
control group (approximately 20% vs 15%). It is unknown which
proportion of the non-attenders in the study group missed
multiple rounds (Andersson, 2002). Including more detailed
information in the model will lead to better estimates of the effect
of shortening the screening interval.
In addition, only one simulation model was used to estimate the
effect of 1-year vs 3-year screening intervals. Having multiple
models that come to similar findings might have strengthened the
conclusion of the present study.
Despite these limitations, the microsimulation model, used in
this study, adequately simulated the number of screen detected
and interval cancers in both arms of the trial. Moreover, the
predicted numbers of breast cancer deaths from cancers diagnosed
in the trial were of the same magnitude as that of the reported
numbers in both groups (Duffy and Blamey, 2008), and the
predicted RR is within the 95% CI of the estimate reported from
the trial.
The UK Breast Screening Frequency Trial showed a nonsigni-
ficant 7% reduction in breast cancer deaths in the study vs the
control group (Duffy and Blamey, 2008), whereas the present study
finds a substantially larger effect of shortening the screening
interval (17%). The question arises why the model outcomes differ
from the trial results. Several factors might contribute.
First, the RR predicted by the model is within the 95% CI of the
trial-reported RR, indicating that the predicted RR is not
statistically different from the trial-reported RR. The Frequency
Trial invited 99 389 women, based on an expected 25% difference
in breast cancer mortality between the study and control group
(Day and Duffy, 1996). The current study shows that this estimated
difference of 25% was too optimistic, suggesting that the trial was
underpowered to find a significant difference between the two
groups. On the basis of the results of the current study (i.e., an RR
of 0.83), approximately 945 000 women needed to have been
invited for a power of 80% to demonstrate a significant (P¼ 0.05)
difference in breast cancer mortality between the two groups
(Lwanga and Lemeshow, 1991). However, the trial was designed to
show a difference in predicted mortality, based on surrogate end
points; in this case, the tumour size of the detected cancers. It was
estimated that the sample size can be 2.74 times smaller without
losing precision when surrogate end points are used (Day and
Duffy, 1996). This means that when surrogate end points (such as
prognostic indices) are used, at least 345 000 women needed to
have been invited in order to have 80% power. Our findings
indicate that the number needed to invite can also be reduced by
increasing compliance to screening tests or increasing screening
test sensitivity.
Furthermore, in the trial, more invasive breast cancers were
detected in the study group than in the control group. Thus, more
diagnoses have been moved forward in time in the study group
than in the control group and then, more breast cancer deaths
from cancers diagnosed in trial can be expected in the study group.
An alternative would be to compare the number of breast cancer
deaths from all breast cancers (during a certain follow-up period).
However, after the trial, everyone receives usual care (triennial
screening), resulting in a dilution of the effect on mortality. Both
comparisons will lead to an underestimation of the effect of more
frequent screening (i.e., a bias towards an RR of 1).
The results of the available observational studies are somewhat
contradictory on the effect of shortening the screening interval.
For example, two retrospective studies showed similar prognostic
factors for women screened annually vs biennially (White et al,
2004; Wai et al, 2005). However, two other studies found that
women who were screened annually had breast tumours that were
smaller and less advanced than those who were screened every
other year (Field et al, 1998; Hunt et al, 1999). Furthermore, six
independent models showed that there is some benefit when
moving from biennial to annual screening, although the benefit
diminished (i.e., the benefit of moving from biennial to annual
screening is smaller than that of moving from no screening to
biennial screening). For example, 68–90% of the benefit is
maintained when moving from annual to biennial screening
scenarios for women aged 50–69 years (Mandelblatt et al, 2009).
Thus, the benefit of screening every year is not three times as large
as screening carried out once in every 3 years. The associated
harms and costs also have to be taken into account when
determining the optimal screening frequency and increases more
steeply with more frequent screening than the benefits.
In conclusion, the present study suggests that there is benefit in
terms of a mortality reduction of shortening the screening interval
from 3 years to 1 year. However, the benefit is probably not large
Table 3 Predicted relative risks using different assumptions
Predicted RR
Base run 0.83
Life-time follow-up 0.83
Higher sensitivity 0.81
100% attendance 0.81
Higher sensitivity and 100% attendance 0.77
Abbreviation: RR¼ relative risk.
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enough to start annual screening (Boer et al, 1998). At the same
time, there seems to be no reason to abolish the 2-year interval
currently used in most European screening programmes. For these
programmes, benefits in terms of mortality reductions have been
shown (Otto et al, 2003; Tabar et al, 2003).
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APPENDIX
This appendix consists of three parts:
(1) a model overview containing a description of MISCAN-Fadia,
(2) a description of the model components, and
(3) a description of the model quantifications of each model
component
Model overview
MISCAN-Fadia (MIcrosimulation of SCreening ANalysis – Fatal
diameter) is a microsimulation model generating independent life
histories. It uses the so-called parallel universe approach and first
simulates the individual life histories for women in the absence of
screening and then assesses how these histories would change as a
consequence of a screening program. A certain percentage of the
modelled population develops pre-clinical disease. The natural
history of breast cancer is modelled as a continuously growing
tumour. MISCAN-Fadia includes a sub model for ductal carcinoma
in situ (DCIS), with three different types of preclinical DCIS:
regressive DCIS, DCIS that will be diagnosed clinically, and DCIS
that will progress to invasive disease. When a screening program is
applied, the pre-clinical tumour may be detected by screening if it
is larger than a screen-detection threshold diameter.
Model components
Demographics The demography part of the model simulates
individual life histories without breast cancer to form a population.
For each person, a date of birth and a date of death of other causes
than breast cancer are simulated. The distribution of births and
deaths can be adjusted to represent the population simulated.
Incidence A certain percentage of the modelled population
develops preclinical disease. This percentage varies between birth
cohorts, while the cohorts have the same age distribution of onset
of breast cancer.
Natural history Among women who develop disease, the natural
history of breast cancer is modelled as a continuously growing
tumour. Each tumour has a size (the fatal diameter, which differs
between tumours) at which diagnosis and treatment will no longer
result in cure given available treatment options. If the tumour is
diagnosed (either on the basis of clinical presentation with
symptoms or by screening) and treated before the tumour reaches
the fatal diameter, the woman will be cured and will die of non-
breast cancer causes (Appendix Figure A1). Variation between
tumours is modelled by probability distributions of tumour
growth rate, threshold diameter of screen detection, clinical
diagnosis diameter, fatal disease diameter, and survival duration
since fatal diameter.
Screening When a screening program is applied, the preclinical
tumour may be detected by screening. Each simulated tumour has
a diameter at which it will be clinically diagnosed and a screen-
detection threshold diameter. For the latter, screening test
sensitivity is 0% below and 100% above this diameter. The
threshold diameter is dependent on the calendar year and age of
the woman (decreasing with calendar year and older age).
Screening benefits result from detection of more tumours at a
non-fatal size. The characteristics of organized screening pro-
grams, such as screening ages, screening interval and attendance
can be specified, and the type of screening (e.g., ‘organized’ or
‘opportunistic’) can be defined in the model.
Treatment The benefit of adjuvant treatment is modelled as a
shift in the fatal diameter for treated women. For each adjuvant
treatment a cure proportion is estimated (depending on age).
These cure proportions are then translated into corresponding
fatal diameters (i.e., a more effective treatment can cure a larger
tumour). The dissemination of adjuvant treatment is modelled as
the probability of being treated with a certain type of treatment
(e.g., chemotherapy, tamoxifen).
Model quantification
Demographics A female population born between 1930 and
1942 (thus, age 50–62 in 1992) was simulated. We assumed that
all cohorts were represented in equal proportions. Each woman is
assigned a date of death due to non-breast cancer causes based
on the UK female population cohort life tables. These life tables
were available from the Human Mortality Database (Human
Mortality Database, www.mortality.org). The simulated woman
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Figure A1 The MISCAN-Fadia natural history model. The model is
illustrated by a woman who is diagnosed with incurable breast cancer and
for whom screening could have been beneficial. The natural history of
breast cancer is simulated through the random selection of six variables
from probability distributions, denoted by the various curves: onset¼ age
at tumour onset, growth rate¼ tumour growth rate, survival¼ duration
between the moment at which the tumour reaches the fatal diameter and
the moment of death from breast cancer (not shown), clinical diagn
diam¼ tumour diameter at which the tumour will be diagnosed clinically
because of the primary tumour, fatal diam¼ tumour diameter at which
available treatment options will no longer result in cure, threshold
diam¼ tumour diameter at which the tumour becomes screen detectable.
After onset the tumour starts growing exponentially according to the
tumour growth rate. The diagnosis results from the clinical diagnosis
diameter combined with the tumour growth rate. If the tumour is
diagnosed after it has reached the fatal diameter, the woman will die from
breast cancer. Survival is modelled since fatal diameter. For observed
survival (shown), the time between clinical diagnosis and the moment the
tumour has reached its fatal diameter has to be subtracted. Screening can
change this natural history: After the tumour has reached the threshold
diameter, the tumour can be screen detected. If the tumour has not
reached the fatal diameter yet at the moment of screen detection, the
woman will be cured. Otherwise, screening will not affect the woman’s age
of death. Reprinted from Tan et al, 2006 with permission from Oxford
University Press.
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dies because of breast cancer or of other causes, whichever
comes first.
Incidence We used age-specific breast cancer incidence rates for
the years 1975–1988, i.e. before the implementation of the
National Health Service Breast Screening Programme to estimate
age-specific onset parameters for the onset of breast cancer.
Natural history All parameters were previously estimated using
detailed data from the Two County Study (Tabar et al, 1992; Tan
et al, 2006). Subsequently, the fatal diameter was calibrated to U.S.
data concerning 1975 stage distribution and 1975 survival (SEER
data) (Tan et al, 2006).
For the present study, we re-estimated two parameters: the
diameter at clinical diagnosis and the screening threshold
diameters. We re-estimated these parameters, because these
parameters can vary across countries and over time, whereas
other parameters (e.g., the tumour growth rate) are assumed to be
more or less universal. To estimate these two parameters we used
the following data from the UK Frequency Trial:
 The number of detected invasive cancers over time in both
groups (control & study group).
 The total number of invasive cancers by tumour size and
detection mode in both groups.
The estimated values of the diameter at clinical diagnosis and the
screening threshold diameters are shown in Appendix Table A1.
The estimated values for these parameters are somewhat higher
than the values previously found based on data from the Two
County Study (Lognormal (0.8, 0.6) and Weibull (1.0, 3.0) for the
diameter at clinical diagnosis and the screening threshold
diameter, respectively) (Tan et al, 2006). If these lower values
are used to simulate the Frequency Trial, a more favourable
tumour size is simulated than the one that is observed in the trial.
Screening In the present study we simulated the screening in the
UK Breast Screening Frequency Trial using previously published
attendance rates. The attendance rate in the control group, among
women who had attended the prevalence screen, was 85%. In the
study group, attendance rates at the three yearly screens were 78,
78, and 81%, respectively (Breast Screening Frequency Trial
Group, 2002).
Treatment We used treatment effectiveness data based on meta-
analyses of the Early Breast Cancer Trialists’ Collaborative Group
(Early Breast Cancer Trialists’ Collaborative Group, 1998a, b). The
dissemination of adjuvant treatment (the probability of being
treated with a certain type of treatment) was based on data from
the US (Mariotto et al, 2006).
Table A1 Maximum likelihood estimates for MISCAN-Fadia natural history parameters and the data sources used to estimate the parameter distribution.
Variable Distribution Mean s.d. Data used (ref)
(a) Parameter estimates and their distribution
Growth rate (1/year) Lognormal (0.062, 0.87) 1.6 1.7 TCS (Tabar et al, 1992; Tan et al, 2006)
Fatal diameter (cm) Weibull (4.0, 0.95) 4.1 4.3 SEER (Tan et al, 2006)
Survival duration since fatal diameter (years) Lognormal (2.4, 1.1) 22 35 TCS (Tabar et al, 1992; Tan et al, 2006)
Diameter at clinical diagnosis because of primary tumour (cm) Lognormal (0.88, 0.6) 2.8 1.8 Freq (Breast Screening Frequency
Trial Group, 2002)
Screening threshold diameters (cm) Age 50–59 Weibull (1.33, 2.95) 1.2 0.4 Freq (Breast Screening Frequency
Trial Group, 2002)
Age 60–65 Weibull (1.05, 2.95) 0.9 0.3 Freq (Breast Screening Frequency
Trial Group, 2002)
Variable q
(b) Correlation between variables
Growth rate – survival 0.9 TCS (Tabar et al, 1992; Tan et al, 2006)
Growth rate – clinical diagnosis diameter because of the primary tumour 0.41 TCS (Tabar et al, 1992; Tan et al, 2006)
Clinical diagnosis diameter because of the primary tumour – survival 0.43 TCS (Tabar et al, 1992; Tan et al, 2006)
(c) Time since start of fatal disease at which metastases lead to clinical
diagnosis of the tumour (fraction of the total survival time after reaching
the fatal diameter)
0.9 TCS (Tabar et al, 1992; Tan et al, 2006)
Abbreviations: TCS¼ two county study; s.d.¼ standard deviation; SEER¼ surveillance, epidemiology and end results; Freq, UK breast screening frequency trial.
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